{"name":"Knopp Biosciences","slug":"knopp-biosciences","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiyAJBVV95cUxQVlZmM3hKUVRqX2duZFJna2RmWkdpUzVFZjNHZWplMnRHVVVqSHE5NG1vUldNaEx2ZjhoOW13cWtNWkg5NkJ6Y0ptVTMzeTc1eDBkWHUwTHpseVRVSDI3T0xXeFNhS1ktX2RlMmphZVJiNXQ5aF9zQnV0Y29kdHNJWUdQdnFDWVJmSXFSZ1p5ZXBRRmJTTHBfaE9vX0k4a0RadjBDZzNSeFRZSEpwYTNNc1lWRzFudlg1NWFKbEFQaW5ZY3YyYmFnRGg0RXJFMjVrR2prSmt0MU1PeVZxYW5uUTZLa2ZKT3QyQ3dRLUs2Vm5qRzFmeXVhT1JWejBmeERaQkFsQ21ub1FEM0FHeEotc2dEbk14U2d2ZWlOOGg4RTRVRS1pLVZDLU54YlR0TVkxTTdJZVpqWDNqSDlvY3UtY2s0R1A4eFlj?oc=5","date":"2026-04-07","type":"pipeline","source":"Barchart.com","summary":"Eosinophilic Esophagitis Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Regeneron Pharma, Sanofi, Bristol-Myers Squibb, Ellodi Pharma, AstraZeneca, Allakos, EsoCap, Pfizer - Bar","headline":"Eosinophilic Esophagitis Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Regeneron Pharma, Sanofi,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQWWN5QnhRTDByZmxHMS03MG10ZkY5N2xDWUZuUElYaFpERHFiX3JLZGhsYWZxeU44R3FKbElvaXVGRzVfQk1SR2p4VndaTmJJMU9FZElSUEllelZNa3E1OEZUUWZpQlVJRUU1UjFESTh5WFI3cnEzREpnalB3cmZSaWtBU1hQZlIxNkxwYzQza3ZpeG55N0w2QXJXb05IQi1hUWZxRjVR?oc=5","date":"2025-09-16","type":"trial","source":"fiercebiotech.com","summary":"Areteia posts phase 3 asthma win for potential oral rival to biologic blockbusters - fiercebiotech.com","headline":"Areteia posts phase 3 asthma win for potential oral rival to biologic blockbusters","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPTDYzc1htUGJ0dVRaMWZ6ajZJSVFxOHVyNlZVTFpKbElMUmU5eTBDRW41RTFkMUxyRnUwYkxTQ2EzZC1ndEZQZjFlbGN3MU1pSmx1c0p6OExxcHdxdTdBSmFjNG90Nk9zc1Z2YzZaajBHWVZQNFNwVEwwZjFKS3hreXZhM1dXSGpzUE9ZOUdhM0hyMDF0?oc=5","date":"2024-06-27","type":"pipeline","source":"BioPharma Dive","summary":"These microscopic tunnels are a goldmine for new medicines - BioPharma Dive","headline":"These microscopic tunnels are a goldmine for new medicines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxQZVBLWDNSM1lQWUtIbFBxX3Z0VURQbjBIa0RVXzZWZkxWOWUta2NPZE1MRUdMZXpqM2Z4Qjl4cHJFUUhYWjdTcUJmYUJTeWFWdmxiVl9OcXR6dEpPZXVWWWNmQk5CRC1SVGhfS19nTlI2bl9qWGtGR3JxUlp4aHBtc1lwX0dDdjY2NDc1MnZ6Y0VOVnZSalNZRV8yUjJ5SVVBWVY1NE02OURLLXlKaUxkMkNreVozSjZ0QmdvLTJtOUtfcnhoMDZ0Yg?oc=5","date":"2023-11-08","type":"pipeline","source":"Healio","summary":"XEN1101 significantly reduced monthly seizures for adults with focal-onset epilepsy - Healio","headline":"XEN1101 significantly reduced monthly seizures for adults with focal-onset epilepsy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE96eEs2WEFMeU9iNFJMZWJCZEdvWkVMOFFSYWpweW9sZjNuYjFiNzBaS3A0RkhhN21DYzhrdS1CT21fY0xpZW1fd3hIYTRsSkxQby1XOWFnQnUzQnppeVV4ck9pWVF6b2lTdlE?oc=5","date":"2022-10-31","type":"pipeline","source":"Wiley Online Library","summary":"Does long‐term phenytoin have a place in Dravet syndrome? - Wiley Online Library","headline":"Does long‐term phenytoin have a place in Dravet syndrome?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxPeW14MmNCSnJycDBBSUF5YXZqcFVLMTBUZjg3TEdZd1liUjV5aUtxN0JQclJQNHJLVDNRelpYU3BERmR0T2M5OWJWZ1pXeHlLc0tWT1pZNUxPSHg4eFJ6cGgwNXFWTGx6VVBxYXg3TGxPWHNRNHVGZTgyV0xZcU5KNnRXalBpY1NtNzh3eldYb0ZLemNzTEUzMTQ5ci04WWEyY2JScGVYLUl2V1RXTk9xZFlNa29RbjE3WnhscTdwYm84QVlHZTVxR1ktcWU?oc=5","date":"2022-07-14","type":"deal","source":"Smart Business Dealmakers","summary":"Knopp Biosciences and Population Health Partners Create Areteia Therapeutics - Smart Business Dealmakers","headline":"Knopp Biosciences and Population Health Partners Create Areteia Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPNTM0R01hdWRKMHVHUkFaM0JRN3JlcWNfckNkSHhpREpSeURiRldsSWNldWdIb0x2RlpTWW5PZVctUVRqcmZBZkt3RFBJem5zNG1KZ3I5TWVZNWdob1Q1aC1LN3dfUjBSWUR2NTd0RTZSUXRaSU5nc2tyYWJXUGZmOU1LcGtQQmIxaDNTX0swbERjUXhKM0lXY2RvN3U0UWhxX3M5R2xTV1hSajZaZ1JHQW9BZDVibERHSmNnazZNTXVmdXlDbE9N?oc=5","date":"2022-07-12","type":"deal","source":"baincapital.com","summary":"Knopp Biosciences and Population Health Partners Create Areteia Therapeutics, New Clinical-Stage Asthma Company, with $350 Million in Funding - baincapital.com","headline":"Knopp Biosciences and Population Health Partners Create Areteia Therapeutics, New Clinical-Stage Asthma Company, with $3","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQa3ZqRmRvS0NfRjRkblgwRDRXcnFtMTNRaWFpZnROZGRPR1BFaVE0NE9kRmhYMzJkajJuMGFyUVFpY0dmMW5oeUFXZTRMTldJSXBOMEhCWnRzdVE5OTR0RlhfX05wYWM0UGh5MVRBeDQtS01LeVdVOEVTOTNsN1QzNDFVT2l3Zw?oc=5","date":"2022-07-12","type":"pipeline","source":"BioSpace","summary":"Knopp, Population Health Launch Areteia to Breathe New Life into Old Molecule - BioSpace","headline":"Knopp, Population Health Launch Areteia to Breathe New Life into Old Molecule","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNZDFXaVdBUTkxZjcwY2FMb2QtTTFHWE1tUl9icDdVZkJJYlRXYjdrXzd1aE1ZNXNfdXJfeFBrR3lxRFZjdzNya3pmWV9tdnVYUC1mbktFazJKa0VCNTk4VGRKS0ZvRmVqclp3dTEtUjl4TTRqQ3hZWHlqNVo1WjNwekIxOUJ2bU83dkROX0xuX0RxUjFIcFY3ZmgtakszdkJRd2pCSks2Uk1MYUhibmc?oc=5","date":"2022-05-16","type":"deal","source":"Pharmaceutical Technology","summary":"These were the biggest pharmaceutical deals in early 2022 - Pharmaceutical Technology","headline":"These were the biggest pharmaceutical deals in early 2022","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQckJPLTVNaEMwM3p3emtITTVNSkQ1M09xcDB2MDZ0bW0wNy1UZ3MyWjBVZEdJQ3VYaEc5ZXk2X1dsd08yM2p0LW1ETlEtNVVsOWdUX0daQTdFaldmRzFMZzM0UmlhbGFxSHdrTk9tc2wzeGZOLXRyX1ZUWkIxTWJzb3QtRHNpQ3lDSTN4b09oS0lNdERkYVlpV3c0TGRVVFR2VnY5WVNDWkN0ajBhRDBvcXFDODUwc2tGanAw?oc=5","date":"2022-02-26","type":"deal","source":"The Pharma Letter","summary":"Busy day for Biohaven, with proposed buy of Channel Biosciences and BMS deal - The Pharma Letter","headline":"Busy day for Biohaven, with proposed buy of Channel Biosciences and BMS deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwJBVV95cUxNaEMtZGNsQkdZS2xMa0l1MWNsMHdGOFl4MG1ianQyOHZkUHFfYVBfN3ZRdEZDSVV1OG5SNXFrOER0TVFpUUt6MnZGamRUdjc2TnBYZG9zYi1aZnAxMXVtckxUZGtFaWZVS0psdDE3YWw3ekFHX3RfWGstTkR2bFdORzczRlBXdmcweDVIVU9wMnp0X2FMU1NnZHJ1Y0FmTFNPNnlEOGxmaUJ4OEY0Z0RKQnhsUlpvNF9aT2s2UmNMdDl2NkxfRHNJZ2xPRUV3THUyTDYwT3IzNHJtYjFFNUpwblpydFVDTWJzWnFwME13QmhoUTM5dkthZnBmM3ZPaXJZU2ZORlBlbURmeWFsRFI4RlVJTWFpN3YxMnY5NWNndEludmVOY1ZaLUxzVzZfNUtLTkVianowNFNubldldnZR?oc=5","date":"2022-02-25","type":"deal","source":"prnewswire.com","summary":"Biohaven Acquires Kv7 Ion Channel Platform for the Treatment of Epilepsy and Other Neurologic Disorders From Channel Biosciences, a Subsidiary of Knopp Biosciences - prnewswire.com","headline":"Biohaven Acquires Kv7 Ion Channel Platform for the Treatment of Epilepsy and Other Neurologic Disorders From Channel Bio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNN184enJHOXJ6VVNNWEdnaDFHQndIckxOME1lTi1uWm40bmMyOFhVUVM3T1RMb3FJM1NBWFNBd1V1aGpNWGVIRVFrLWxiU05uaWF2YlVSODFXVnF5QWtGRFFLYk5uSWx5U2tjN2FMaEFUZkhLSFRLSnJNZnZ6eGRSWGY4dzFxV0hHUW1hTXI5SlN6eTBMeC1VSno5bnFPRUd0bHlKMktMbmdsdGVVODRKT2MyRVJrbmhaTGV0aHlJc2E?oc=5","date":"2019-06-14","type":"trial","source":"Biogen","summary":"Biogen Idec and Knopp Biosciences Announce Enrollment of the First Patient in a Global Phase III Study of Dexpramipexole for ALS - Biogen","headline":"Biogen Idec and Knopp Biosciences Announce Enrollment of the First Patient in a Global Phase III Study of Dexpramipexole","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}